Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 5

Optimizing prophylactic treatment of migraine: Subtypes and patient matching

Authors Michel Dib

Published 10 October 2008 Volume 2008:4(5) Pages 1061—1078

DOI https://doi.org/10.2147/TCRM.S3983

Review by Single-blind

Peer reviewer comments 3

Michel Dib

Fédération du système nerveux central, Hôpital de la Salpêtrière, Assistance Publique- Hôpitaux de Paris, France

Abstract: Advances in our understanding of the pathophysiology of migraine have resulted in important breakthroughs in treatment. For example, understanding of the role of serotonin in the cerebrovascular circulation has led to the development of triptans for the acute relief of migraine headaches, and the identification of cortical spreading depression as an early central event associated wih migraine has brought renewed interest in antiepileptic drugs for migraine prophylaxis. However, migraine still remains inadequately treated. Indeed, it is apparent that migraine is not a single disease but rather a syndrome that can manifest itself in a variety of pathological conditions. The consequences of this may be that treatment needs to be matched to particular patients. Clinical research needs to be devoted to identifying which sort of patients benefit best from which treatments, particularly in the field of prophylaxis. We propose four patterns of precipitating factors (adrenergic, serotoninergic, menstrual, and muscular) which may be used to structure migraine prophylaxis. Finally, little is known about long-term outcome in treated migraine. It is possible that appropriate early prophylaxis may modify the long-term course of the disease and avoid late complications.

Keywords: migraine, diagnosis, treatment, prophylaxis, subtypes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Management of postoperative ileus: focus on alvimopan

Eric L Marderstein, Conor P Delaney

Therapeutics and Clinical Risk Management 2008, 4:965-973

Published Date: 10 October 2008

Risk management profile of etoricoxib: an example of personalized medicine

Paola Patrignani, Stefania Tacconelli, Marta L Capone

Therapeutics and Clinical Risk Management 2008, 4:983-997

Published Date: 10 October 2008

Pharmacological management of acute bronchiolitis

Melvin Wright, Charles J Mullett, Giovanni Piedimonte

Therapeutics and Clinical Risk Management 2008, 4:895-903

Published Date: 10 October 2008

A systematic approach of tracking and reporting medication errors at a tertiary care university hospital, Karachi, Pakistan

Khurshid Khowaja, Rozmin Nizar, Rashida J Merchant, Jacqueline Dias, Irma Bustamante-Gavino, Amina Malik

Therapeutics and Clinical Risk Management 2008, 4:673-679

Published Date: 8 August 2008

Combating HIV resistance – focus on darunavir

Cécile L Tremblay

Therapeutics and Clinical Risk Management 2008, 4:759-765

Published Date: 8 August 2008

Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective

Fabio Ferrarese, Gioia Becchimanzi, Massimo Bernardo, Maria Anna Conte, Angela Gioia, et al

Therapeutics and Clinical Risk Management 2008, 4:665-671

Published Date: 8 August 2008

Resveratrol in prevention and treatment of common clinical conditions of aging

M Andrea Markus, Brian J Morris

Clinical Interventions in Aging 2008, 3:331-339

Published Date: 6 June 2008

Editorial  ||FREE PAPER||

Garry M Walsh

Therapeutics and Clinical Risk Management 2008, 4:0-0

Published Date: 6 June 2008

Targeting CD22 as a strategy for treating systemic autoimmune diseases

Thomas Dörner, David M Goldenberg

Therapeutics and Clinical Risk Management 2007, 3:953-959

Published Date: 15 November 2007